Low-dose radiation to the whole lungs for severe COVID
Part of Infections, Lungs & breathing clinical trials.
This Phase 2 study tests whether low-dose whole-lung radiation can improve outcomes for people with severe COVID-19 lung problems who are on ICU breathing machines. It’s designed for patients with new COVID symptoms and low oxygen levels despite critical care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were diagnosed with COVID-19 by lab test within the last 14 days
- You have recent chest scan findings typical for COVID pneumonia within the last 5 days
- You are in the ICU and are on a breathing machine (mechanical ventilation)
- Your oxygen levels are low enough to meet specific thresholds from blood or oxygen measurements
- A doctor expects you can live at least 24 hours and likely at least 30 days for trial purposes
- You (or your legal representative) can sign informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how COVID-19 infection might affect lung inflammation caused by radiation therapy in breast cancer patients. If you are being treated for breast cancer with radiation and have had or may get COVID-19, this study can help understand these risks.
This trial tests whether adding a low dose of radiation to the liver can make standard immunotherapy work better for people with non-small cell lung cancer or melanoma that has spread to the liver.
This trial tests a low dose of radiation to the chest followed by a combination of an immunotherapy drug (adebrelimab) and chemotherapy for extensive-stage small cell lung cancer. Afterward, you would continue taking adebrelimab alone as maintenance therapy.
This trial tests a new way to plan radiation therapy for lung cancer by using a special imaging technique (functional lung imaging) to see which parts of your lungs work best. The goal is to reduce damage to healthy lung tissue while still targeting the cancer.
This trial studies whether a more intensive form of targeted radiation, combined with immunotherapy (immune checkpoint inhibitors), can work better and be safe for people with advanced non-small cell lung cancer. You may be considered if your tumor is limited in size and you’re able to receive both treatments.
This trial tests a new approach for advanced non-small cell lung cancer that cannot be surgically removed. It combines a focused, high-dose radiation treatment to the tumor core followed by standard chemotherapy and radiation together. This may help fight the cancer more effectively.
Hear when a new COVID-19 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.